Cannabinoids and an Anti-inflammatory Diet for the Treatment of Neuropathic Pain After Spinal Cord Injury

Model scores of the 29,894 trials active now.

Model score 16% for any early termination, 9% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 17% of the time (276 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2024-12-01. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: painplaceboinjuryneuropathiccord
  Phrases that lowered it: ulnparticipantsaminotransferasepatientsalt
• Accepts healthy volunteers: No (raises risk) · Who can join
• Minimum age: 25 (lowers risk) · Who can join
• Design: factorial (lowers risk) · Design
• Sponsor's past termination rate: no earlier finished trials (lowers risk) · Sponsor's track record
• Responsible party: sponsor investigator (raises risk) · Design
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Disease area, neurology: Yes (raises risk) · Disease area
• Blinding: triple (raises risk) · Design
• Phase: 3 (lowers risk) · Design
• Number of arms: 4 (lowers risk) · Design
• Drug's FAERS reports marked serious: 97.9% (raises risk) · Drug's FDA history
• Drug's FAERS reports with a death: 6.1% (lowers risk) · Drug's FDA history
• Disease area, cancer: No (lowers risk) · Disease area
• Trials the sponsor started in the prior 2 years: 0 (raises risk) · Sponsor's track record
• Primary purpose: treatment (raises risk) · Design
• Sponsor's past trials: 0 (lowers risk) · Sponsor's track record
• Has a data monitoring committee: No (lowers risk) · Design
• Collaborators: 1 (raises risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Effect of Cannabinoids on Spasticity and Neuropathic Pain in Spinal Cord Injured Persons NCT01222468 · started 2012 · scored riskier than 13% of active trials completed
• NVG-291 in Spinal Cord Injury Subjects NCT05965700 · started 2023 · scored riskier than 79% of active trials completed
• Effects of CBD/CBD-A Oral Extract on Resting-state EEG and Neuropathic Pain Symptoms After SCI NCT05630235 · started 2025 · scored riskier than 62% of active trials completed
• Comparison of VER-01 to Opioids in Patients With Chronic Non-specific Low Back Pain NCT05610813 · started 2023 · scored riskier than 14% of active trials completed
• Vaporized Cannabis and Spinal Cord Injury Pain NCT01555983 · started 2012 · scored riskier than 40% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.